RT Journal Article
SR Electronic
T1 Evaluating the yaws diagnostic gap: a survey to determine the capacity of and barriers to improving diagnostics in all yaws-endemic countries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.30.22275669
DO 10.1101/2022.05.30.22275669
A1 Handley, Becca L.
A1 Tchatchouang, Serges
A1 Grout, Lise
A1 Johnson, Roch Christian
A1 Tabah, Earnest Njih
A1 Boua, Bernard
A1 Boock, Alphonse Um
A1 Koffi, Aboa Paul
A1 Phanzu, Delphin Mavinga
A1 Kotey, Nana Konama
A1 Rogers, Emerson
A1 Dofitas, Belen
A1 Jung, Younghee
A1 Maweke, Tchalim
A1 Beiras, Camila G.
A1 Maman, Issaka
A1 Basing, Laud Anthony
A1 Ngazoa, Solange
A1 Houezo, Jean Gabin
A1 Togbey, Kwamy
A1 Telan, Elizabeth Freda
A1 Sarmento, Nevio
A1 Marion, Estelle
A1 Addo, Kwasi Kennedy
A1 Mitjà, Oriol
A1 Asideu, Kinsley
A1 Harding-Esch, Emma
A1 Marks, Michael
YR 2022
UL http://medrxiv.org/content/early/2022/05/31/2022.05.30.22275669.abstract
AB Background Yaws, caused by Treponema pallidum subsp. pertenue, is a skin neglected tropical disease. It is targeted for eradication by 2030, primarily using mass drug administration (MDA) with azithromycin. Traditionally, diagnosis of yaws has relied on clinical examination and serological testing. However, these approaches have poor diagnostic performance. To achieve eradication, more accurate diagnostics are required to determine whether MDA should be initiated or continued as well as for post-elimination surveillance. Molecular tools will be crucial for detecting antimicrobial resistant cases, which have the potential to derail eradication efforts. In order to determine the feasibility of introducing novel, more accurate, diagnostics for yaws surveillance purposes, it is necessary to understand current in-country diagnostic capacity. This study therefore aimed to understand the current capacity of, and challenges to, improving diagnostics for yaws in all yaws-endemic countries worldwide.Methodology/ principal findings An online survey was sent to all 15 yaws-endemic countries in July 2021. The survey asked about past prevalence estimates, the availability of different diagnostic tools, and perceived barriers to enhancing capacity. Fourteen countries responded to the survey, four of which did not have a current National Policy for yaws eradication in place. Over 95% of reported that yaws cases from the past five years had not been confirmed with serological or molecular tools, largely due to the limited supply of rapid serological tests. Only four countries reported having operational laboratories for molecular yaws diagnosis, with only one of these having a validated assay to detect azithromycin resistance.Conclusions and Significance This study highlights the diagnostic capacity constraints across all respondent countries. Countries are in need of access to a sustainable supply of serological tests, and development of molecular testing facilities. Sufficient sustainable funding should be made available to ensure that appropriate diagnostic tools are available and utilised.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project is part of the EDCTP2 programme supported by the European Union (grant number RIA2018D-2495-LAMP4Yaws).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not relevant. This work was discussed with the LSHTM Research Governance Office who adjudged it to be a service evaluation not requiring formal review by the LSHTM Ethics CommitteeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors